Furthermore, the synergistic combinations of sudemycins with other anticancer drugs, such as BCL-2/BCL-XL antagonists like ABT-263 or venetoclax, and the inhibitor of Bruton's tyrosine kinase ibrutinib, demonstrated effectiveness in the treatment of chronic lymphocytic leukemia 52, 53. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.